BioSpace News Archive

Product launch and rapid development of the Logix Smart™ 2019-nCoV coronavirus test facilitated by Company’s proprietary technology platform

Collegium Pharmaceutical, Inc. announced that it has entered into a definitive agreement to acquire the U.S. rights to the Nucynta Franchise from Assertio Therapeutics, Inc. for $375.0 million in cash..

Company Intends to Use Improved Balance Sheet to Pursue Business Development, Strategic Partnerships and Investment Opportunities

Anika Therapeutics, Inc. announced that the Company plans to issue its fourth-quarter and full-year 2019 financial results after the close of the market on Thursday, February 20, 2019 and hold its investor conference call on the same day, Thursday, February 20, 2019, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.

Positive results from part 1 of the Phase 1a/b clinical study of EDP-514 in healthy subjects - Part 2 initiated in nuc-suppressed chronic hepatitis B virus patients

Twist Bioscience Corporation announced it has reached a settlement agreement with Agilent Technologies to resolve all claims and counterclaims in the trade secret litigation filed by Agilent on February 3, 2016.

Data shows that patients with > +1.75 ADD power and above age 55 achieved vision comparable to spectacle acuity at every distance with NaturalVue Multifocal

Conference Call and Webcast with Slides Begins at 4:30 p.m. Eastern Time Today

Xencor, Inc. announced that company management will participate in two upcoming conferences

Aduro Biotech, Inc. announced that the company earned a $10.0 million development milestone payment under its worldwide licensing agreement with Merck for the initiation of a Phase 2 clinical trial of MK-5890, an anti-CD27 agonist, in non-small cell lung cancer.